Skip to main content

Advertisement

Table 2 Association between the status of plasma Epstein–Barr virus (EBV) DNA during posttreatment follow-up and tumor recurrence in the 385 patients with NPC who were treated with IMRT and stratified by the status of pretreatment plasma EBV DNA

From: Prognostic value of plasma Epstein–Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy

Site of first recurrence Undetectable pretreatment plasma EBV DNA [n (%)] Detectable pretreatment plasma EBV DNA [n (%)]
Undetectable plasma EBV DNA during posttreatment follow-up
(n = 101)
Detectable plasma EBV DNA during posttreatment follow-up
(n = 17)
P Undetectable plasma EBV DNA during posttreatment follow-up
(n = 191)
Detectable plasma EBV DNA during posttreatment follow-up
(n = 76)
P
Any recurrence 4 (4.0) 6 (35.3) 0.001a 15 (7.9) 47 (61.8) < 0.001b
Locoregional 4 (4.0) 4 (23.5) 0.015a 13 (6.8) 18 (23.7) < 0.001b
Distant with or without locoregional 0 (0) 2 (11.8) 0.020a 2 (1.0) 29 (38.2) < 0.001b
  1. a P values were calculated using Fisher’s exact test when any number was < 5
  2. b P values were calculated using the χ² test